glp-1 agonist cardiovascular outcomes and mortality with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia The Big Trial of a

This content should not be taken as personal medical advice or a substitute for consultation with a qualified healthcare provider

Gastrointestinal intolerance, particularly nausea and vomiting, may affect adherence despite their tendency to diminish over time (Liu et al., 2022)

- Nausea appears to be less common with long-acting than short-acting compounds

Cancer Epidemiol

The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4

Phase 3 clinical trials compared tirzepatide at 5, 10 and 15 mg doses to semaglutide (1 mg) in a 40-week trial of patients with T2D 51